Company Filing History:
Years Active: 2024-2025
Title: Innovator Profile: Ravi JAGASIA in Basel, CH
Introduction: Ravi JAGASIA is a distinguished inventor based in Basel, Switzerland, known for his significant contributions to the field of biotechnology. With a total of three patents to his name, his work predominantly focuses on oligonucleotide-based therapies aimed at addressing neurological disorders. His innovative research is instrumental in developing treatments that may improve patient outcomes.
Latest Patents: Among his latest inventions are two notable patents that explore the therapeutic potential of targeting progranulin, a protein associated with various neurological conditions. The first patent, “Oligonucleotide agonists targeting progranulin,” details the use of oligonucleotides that can up-regulate or restore progranulin expression in cells, making it a promising approach for treating conditions linked to progranulin haploinsufficiency. The second patent, “Antisense oligonucleotide for targeting progranulin,” focuses on oligonucleotides designed to alter the splicing pattern of progranulin, further highlighting his innovative approach to combat neurological disorders.
Career Highlights: Ravi JAGASIA currently works at Hoffmann-La Roche Inc., a leading global healthcare company that emphasizes innovation in pharmaceuticals and diagnostics. His role within the organization allows him to collaborate with some of the brightest minds in the industry, further pushing the boundaries of medical science through innovative therapies.
Collaborations: In his pursuit of groundbreaking research, Ravi collaborates with esteemed colleagues such as Congwei Wang and Christian Weile. Their combined expertise fosters an environment of innovation, driving the development of effective treatments and enhancing the understanding of complex biological mechanisms.
Conclusion: Ravi JAGASIA's contributions to the field of biotechnology underline his commitment to improving health outcomes through innovation. With his focus on oligonucleotide research and collaboration within Hoffmann-La Roche Inc., he continues to pave the way for novel therapeutic approaches addressing critical neurological issues. His work stands as a testament to the power of innovation in creating impactful solutions in medicine.